Drugs / Zidovudine
last change Dec 2025 re-read 2 minutes ago

Zidovudine

Small molecule

Developed for
HIV infectious disease · AIDS · Kaposi's sarcoma · lipodystrophy · lymphoma · AIDS dementia complex · tuberculosis · non-Hodgkin lymphoma
+20 more · adult T-cell leukemia/lymphoma · Aicardi-Goutieres syndrome · AIDS related complex · brain disorder · cytomegalovirus retinitis · Epstein-Barr virus-associated lymphoproliferative disorder · hepatitis B virus infection · human herpesvirus 8 infection · KSHV inflammatory cytokine syndrome · lymphoproliferative syndrome · multicentric Castleman disease · neuromuscular disease · post-transplant lymphoproliferative disease · primary biliary cholangitis · progressive multifocal leukoencephalopathy · psoriasis · tropical spastic paraparesis · cancer · central nervous system disorder · dementia
Investigated by
National Institute of Allergy and Infectious Diseases (NIAID) · Glaxo Wellcome · Bristol-Myers Squibb · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · Hoffmann-La Roche · Gilead Sciences
+115 more · Merck Sharp & Dohme LLC · National Cancer Institute (NCI) · Abbott · Boehringer Ingelheim · GlaxoSmithKline · Harvard School of Public Health (HSPH) · Pharmacia and Upjohn · University of Miami · ANRS, Emerging Infectious Diseases · French National Agency for Research on AIDS and Viral Hepatitis · G D Searle · International Maternal Pediatric Adolescent AIDS Clinical Trials Group · Kirby Institute · Makerere University · Research Institute for Development · Upjohn · ViiV Healthcare · AIDS Malignancy Consortium · Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections · Amgen · Genentech, Inc. · International Antiviral Therapy Evaluation Center · National Center for AIDS/STD Control and Prevention, China CDC · National Heart, Lung, and Blood Institute (NHLBI) · Sandoz · St Vincent's Hospital, Sydney · University of California, San Diego · AIDS Project Los Angeles · Amsterdam UMC, location VUmc · Assistance Publique - Hôpitaux de Paris · Axcan Pharma · Beijing YouAn Hospital · Biogen · Botswana Harvard Health Partnership · Botswana Ministry of Health · Brigham and Women's Hospital · CIHR Canadian HIV Trials Network · Centers for Disease Control and Prevention · Centre Hospitalier Universitaire Saint Pierre · Centre de Sante de Ziguinchor, Casamance, Senegal · Centro di Riferimento Oncologico - Aviano · China Medical University, China · Chiron Corporation · Chulalongkorn University · Clinique des Maladies Infectieuses, CHNU de Fann, Dakar, Senegal · Department for International Development, United Kingdom · Doris Duke Charitable Foundation · Duke University · Dupont Merck · Fight AIDS and Infectious Diseases Foundation · First Affiliated Hospital of Guangxi Medical University · Fundacion SEIMC-GESIDA · Garvan Institute of Medical Research · Genelabs Technologies · Germans Trias i Pujol Hospital · Guangdong Provincial Maternal and Child Health Hospital · HIV Prevention Trials Network · Hoechst Marion Roussel · Infectious Diseases Institute, Uganda · Initiative Senegalaise d'Acces aux Antiretroviraux (ISAARV) · Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba · Janssen Pharmaceutica · Janssen Research & Development, LLC · Janssen-Cilag GmbH · Johann Wolfgang Goethe University Hospital · Kibongoto National Tuberculosis Hospital, Tanzania · Kilimanjaro Christian Medical Centre, Tanzania · Los Angeles County Department of Public Health · Los Angeles LGBT Center · Maternal and Child Health Hospital of Guangxi Province · Maternal and Child Health Hospital of Sichuan Province · Maternal and Child Health Hospital of Xinjiang Uygur Autonomous Region · Maternal and Child Health Hospital of Yunan Province · Mbarara University of Science and Technology · all 121 on the full record

Regulatory milestones approvals, filings & regulatory actions · 9 recorded

MilestoneJurisdictionBrandIndicationDateSentence it was read from
Label expansions (7) US (FDA) RETROVIR 1990-01-12 – 2009-11-06 fda.gov
Approved EU (EMA) Combivir 1998-03-18 europa.eu
Approved US (FDA) RETROVIR 1987-03-19 fda.gov

Trials 274 · started per year

today
US approved 1987
EU approved 1998
1
3
20
6
10
9
9
13
8
6
10
5
4
6
14
10
14
13
6
10
6
3
3
6
1
1
2
3
2
2
2
1
19871988198919901991199219931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 01 trial
Phase 0 NCT02655471 Jul 2017 → Mar 2019 tropical spastic paraparesis Universidad Peruana Cayetano Heredia Completed No outcome recorded
Phase 151 trials
Phase 1 NCT00470041 Jun 2007 → Oct 2009 University Ghent Completed No outcome recorded
Phase 1 NCT02249416 Nov 2001 → Feb 2002 Boehringer Ingelheim Completed No outcome recorded
Phase 1 NCT00001644 Mar 1997 → Feb 2010 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 1 NCT00000978 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 1 NCT00000888 ? → Apr 2001 HIV infectious disease, pregnancy disorder National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 1 NCT00000818 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 1 NCT00000800 ? → Oct 1998 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 1 NCT00000696 ? → Nov 1993 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 1 NCT00000742 ? → Oct 1993 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 1 NCT00000652 ? → Nov 1995 HIV infectious disease National Cancer Institute (NCI) Completed No outcome recorded
Phase 1/22 trials
Phase 1/2 NCT00672412 Oct 2008 → Jan 2010 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 1/2 NCT00432016 Feb → May 2007 HIV infectious disease RFS Pharma, LLC Completed No outcome recorded
Phase 270 trials
Phase 2 NCT03922724 Apr 2019 → Jun 2027 expected lymphoproliferative syndrome, peripheral T-cell lymphoma, not otherwise specified National Cancer Institute (NCI) Recruiting No outcome recorded
Phase 2 NCT03602690 Oct 2018 → Apr 2022 HIV infectious disease ANRS, Emerging Infectious Diseases Unknown No outcome recorded
Phase 2 NCT02737046 Dec 2016 → Dec 2024 adult T-cell leukemia/lymphoma University of Miami Completed No outcome recorded
Phase 2 NCT02363452 Sep 2015 → Jan 2018 Aicardi-Goutieres syndrome Assistance Publique - Hôpitaux de Paris Completed No outcome recorded
Phase 2 NCT01441063 Sep 2011 → Jun 2018 multicentric Castleman disease National Cancer Institute (NCI) Completed No outcome recorded
Phase 2 NCT01419561 Sep 2011 → Dec 2028 expected KSHV inflammatory cytokine syndrome, human herpesvirus 8 infection National Cancer Institute (NCI) Recruiting No outcome recorded
Phase 2 NCT00949234 Mar → Jun 2010 HIV infectious disease University of California, Los Angeles Completed No outcome recorded
Phase 2 NCT01964755 Apr 2009 → Jun 2018 Epstein-Barr virus-associated lymphoproliferative disorder, post-transplant lymphoproliferative disease University of Miami Terminated No outcome recorded
Phase 2 NCT00270296 Jun 2006 → Mar 2009 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 2 NCT00109590 Jun 2006 → Oct 2008 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 2/35 trials
Phase 2/3 NCT02150993 Jan 2016 → May 2019 ANRS, Emerging Infectious Diseases Completed No outcome recorded
Phase 2/3 NCT02369406 May 2015 → Nov 2020 overdue AIDS Harvard School of Public Health (HSPH) Active not recruiting No outcome recorded
Phase 2/3 NCT00624195 Mar 2007 → Feb 2012 HIV infectious disease University of California, San Diego Completed No outcome recorded
Phase 2/3 NCT00490620 Jan 2004 → Apr 2007 primary biliary cholangitis University of Alberta Completed No outcome recorded
Phase 2/3 NCT00039741 Aug 2002 → Aug 2009 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 341 trials
Phase 3 NCT03988452 Jul 2019 → Sep 2020 HIV infectious disease Makerere University Unknown No outcome recorded
Phase 3 NCT02231281 Aug 2014 → Aug 2018 Yongtao Sun, MD, PhD Unknown No outcome recorded
Phase 3 NCT01352715 Mar 2012 → Oct 2014 HIV infectious disease Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections Completed No outcome recorded
Phase 3 NCT01511237 Dec 2011 → Jun 2015 HIV infectious disease Research Institute for Development Completed No outcome recorded
Phase 3 NCT01516970 Nov 2011 → Aug 2013 HIV infectious disease Janssen-Cilag GmbH Completed No outcome recorded
Phase 3 NCT01440569 Sep 2011 → Aug 2012 AIDS Gilead Sciences Completed No outcome recorded
Phase 3 NCT00573001 Jul 2008 → Jul 2011 HIV infectious disease French National Agency for Research on AIDS and Viral Hepatitis Completed No outcome recorded
Phase 3 NCT00102960 Jul 2005 → Sep 2012 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 3 NCT00074581 Feb 2005 → May 2015 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 3 NCT00323544 Oct 2004 → Jun 2007 HIV infectious disease Gilead Sciences Completed No outcome recorded
Phase 435 trials
Phase 4 NCT06337032 Aug 2024 → Mar 2034 expected HIV infectious disease Gilead Sciences Recruiting No outcome recorded
Phase 4 NCT03642704 Feb 2017 → Sep 2019 ANRS, Emerging Infectious Diseases Completed No outcome recorded
Phase 4 NCT02712801 Apr 2016 → Dec 2021 HIV infectious disease National Center for Women and Children's Health, China CDC Completed No outcome recorded
Phase 4 NCT01275625 Jun 2011 → Oct 2012 HIV infectious disease ViiV Healthcare Completed No outcome recorded
Phase 4 NCT01075152 Nov 2010 → Oct 2012 AIDS, Cryptococcal meningitis University of Minnesota Completed No outcome recorded
Phase 4 NCT00955968 Jan 2010 → Aug 2016 HIV infectious disease International Maternal Pediatric Adolescent AIDS Clinical Trials Group Completed No outcome recorded
Phase 4 NCT00753324 May 2009 → Jan 2012 HIV infectious disease University of North Carolina, Chapel Hill Completed No outcome recorded
Phase 4 NCT01088516 Dec 2008 → Nov 2011 HIV infectious disease University of Zambia Completed No outcome recorded
Phase 4 NCT01772940 Dec 2008 → Oct 2011 HIV infectious disease Centre Hospitalier Universitaire Saint Pierre Completed No outcome recorded
Phase 4 NCT00865475 Dec 2008 → Mar 2013 HIV infectious disease Fundacion SEIMC-GESIDA Completed No outcome recorded
Phase not applicable69 trials
NCT03394196 Jul 2018 → May 2020 University of Washington Terminated No outcome recorded
NCT01344148 Feb 2009 → Jun 2011 AIDS Shanghai Public Health Clinical Center Unknown No outcome recorded
NCT00872872 May 2008 → Apr 2019 Thai Red Cross AIDS Research Centre Completed No outcome recorded
NCT00120510 Jul 2007 → Sep 2009 HIV infectious disease, tuberculosis National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
NCT00100568 Jul 2006 → Jun 2009 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
NCT00100594 May 2005 → May 2007 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
NCT00080522 Feb 2005 → Jan 2007 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
NCT00001119 Oct 1999 → Jun 2004 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
NCT00002411 Mar 1998 → Sep 1999 HIV infectious disease Bristol-Myers Squibb Completed No outcome recorded
NCT00002108 HIV infectious disease Glaxo Wellcome Completed No outcome recorded
Also used as a comparator or background therapy in 133 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 01 trial
Phase 0 NCT00719602 Comparator Aug 2009 → Aug 2013 HIV infectious disease, malaria International Maternal Pediatric Adolescent AIDS Clinical Trials Group Completed No outcome recorded
Phase 121 trials
Phase 1 NCT02832778 Background Nov 2016 → Jan 2018 HIV infectious disease St Stephens Aids Trust Unknown No outcome recorded
Phase 1 NCT02499874 Background Aug 2015 → Oct 2017 HIV infectious disease St Stephens Aids Trust Completed No outcome recorded
Phase 1 NCT00326716 Background Jun 2006 → Jan 2009 HIV infectious disease Bristol-Myers Squibb Completed No outcome recorded
Phase 1 NCT00032669 Background Mar 2002 → Apr 2006 HIV infectious disease National Cancer Institute (NCI) Completed No outcome recorded
Phase 1 NCT00001005 Background ? → Feb 1995 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 229 trials
Phase 2 NCT04731103 Comparator Aug 2022 → Mar 2024 Aicardi-Goutieres syndrome University of Edinburgh Completed No outcome recorded
Phase 2 NCT01125696 Comparator May 2012 → May 2018 HIV infectious disease, hepatitis B virus infection Centers for Disease Control and Prevention Completed No outcome recorded
Phase 2 NCT00799864 Background Jan 2011 → Aug 2022 Janssen Sciences Ireland UC Completed No outcome recorded
Phase 2 NCT00915655 Background Jul 2009 → Sep 2010 HIV infectious disease Tibotec Pharmaceuticals, Ireland Completed No outcome recorded
Phase 2 NCT00110305 Background Jun 2005 → Dec 2011 HIV infectious disease Tibotec Pharmaceuticals, Ireland Completed No outcome recorded
Phase 2/35 trials
Phase 2/3 NCT02016924 Background Jan 2014 → Jun 2025 overdue AIDS Gilead Sciences Active not recruiting No outcome recorded
Phase 2/3 NCT01540240 Comparator Aug 2011 → Dec 2012 HIV infectious disease, poisoning University Hospital, Geneva Unknown No outcome recorded
Phase 2/3 NCT00834457 Comparator Jun 2007 → Jul 2009 Kaposi's sarcoma Parirenyatwa Hospital Completed No outcome recorded
Phase 2/3 NCT00424814 Comparator Mar 2007 → Sep 2011 HIV infectious disease ANRS, Emerging Infectious Diseases Completed No outcome recorded
Phase 2/3 NCT00272480 Comparator Nov 1999 → Jul 2002 tropical spastic paraparesis Imperial College London Completed No outcome recorded
Phase 342 trials
Phase 3 NCT03631732 Comparator Aug 2018 → Aug 2019 HIV infectious disease Gilead Sciences Completed No outcome recorded
Phase 3 NCT03178084 Background Oct 2014 → Nov 2016 HIV infectious disease Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal Completed No outcome recorded
Phase 3 NCT01605084 Background Jun 2012 → Aug 2014 HIV infectious disease Bristol-Myers Squibb Withdrawn No outcome recorded
Phase 3 NCT01363011 Background May 2011 → Jan 2013 AIDS Gilead Sciences Completed No outcome recorded
Phase 3 NCT01061151 Comparator Mar 2011 → Sep 2016 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 417 trials
Phase 4 NCT03088410 Comparator Aug 2016 → Mar 2022 HIV infectious disease, diabetes mellitus Ann & Robert H Lurie Children's Hospital of Chicago Completed No outcome recorded
Phase 4 NCT01818258 Comparator Oct 2015 → Apr 2017 HIV infectious disease, protein-energy malnutrition International Maternal Pediatric Adolescent AIDS Clinical Trials Group Completed No outcome recorded
Phase 4 NCT02431975 Background Aug 2015 → Apr 2020 HIV infectious disease Columbia University Completed No outcome recorded
Phase 4 NCT01618305 Background Sep 2013 → Dec 2018 HIV infectious disease Westat Completed No outcome recorded
Phase 4 NCT01641367 Background Feb 2013 → Nov 2016 HIV infectious disease Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections Completed No outcome recorded
Phase not applicable17 trials
NCT01583439 Background Sep 2012 → Feb 2013 HIV infectious disease Harvard School of Public Health (HSPH) Terminated No outcome recorded
NCT02002286 Background Aug 2011 → May 2013 HIV infectious disease LI Taisheng Completed No outcome recorded
NCT00608569 Background Mar 2009 → Sep 2012 HIV infectious disease Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections Completed No outcome recorded
NCT00428116 Comparator Sep 2007 → Jul 2013 HIV infectious disease University of Washington Terminated No outcome recorded
NCT00346567 Comparator Jun 2006 → Oct 2010 HIV infectious disease Rigshospitalet, Denmark Completed No outcome recorded
Phase not stated1 trial
NCT01776996 Background HIV infectious disease ViiV Healthcare No longer available No outcome recorded

Evidence & citations 12 cited values

Every value below carries the sentence it was read from. 417 sources stand behind the page.

FieldValueCited text
Known as Zidovudine “Generic names: Efavirenz/Emtricitabine/Tenofovir, Lamivudine/Zidovudine, Emtricitabine, Lamivudine, Abacavir/Lamivudine, Zidovudine, Abacavir/Lamivudine/Zidovudine,...” NCT00624195
408

“It may include one or two nucleoside reverse transcriptase inhibitors, such as zidovudine, didanosine, lamuvidine, zalcitabine, stavudine), a non- nucleoside reverse...” NCT00032669

“Additional ARVs provided for use in this study included fixed dose combination lamivudine/zidovudine (3TC/ZDV), lamivudine (3TC), zidovudine (ZDV), tenofovir (TDF), fixed dose...” NCT00955968

“Participants will receive 2 investigator-selected NRTIs, which may include abacavir (ABC), lamivudine (3TC)/zidovudine (ZDV), didanosine (DDI), emtricitabine (FTC), ABC/3TC,...” NCT01363011

“NRTIs included abacavir, emtricitabine, Combivir (lamivudine/zidovudine, coformulated), Epzicom (abacavir/lamivudine, coformulated), lamivudine, stavudine, tenofovir DF,...” NCT01252940

“Investigator selected 2 NRTIs: (1) Zidovudine and lamivudine (Combivir) and (2) tenofovir disoproxil fumarate and emtricitabine (Truvada) will be administered as per the...” NCT00110305

“These study will explore how fast NVP is eliminated from women after delivery and to see if given zidovudine/lamivudine (AZT/3TC) for 1 or 2 weeks after NVP discontinuation can...” NCT00872872

“Children initiated ART using an induction-maintenance approach, starting with open-label four-drug lamivudine, abacavir, NNRTI, plus zidovudine for 36 weeks, then open-label...” NCT02028676

“For those subjects in South Africa and Argentina who were previously receiving Combivir along with maraviroc in Study A4001026, Combivir will be supplied as tablets containing...” NCT01776996

“Participants who will be enrolled in this trial would keep their previous combined antiretroviral therapy, such as zidovudine or stavudine plus lamivudine plus nevirapine or efavirenz.” NCT02002286

“NRTIs may include emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF), zidovudine+FTC/TDF, abacavir (ABC)+TDF, ABC+FTC/TDF, ABC+lamivudine (3TC), or didanosine (DDI)+FTC.” NCT01440569

“receive abacavir sulfate/lamivudine/zidovudine (ABC/3TC/ZDV) twice-daily or atazanavir (ATV) once-daily plus lamivudine/zidovudine (3TC/ZDV) twice-daily.” PMID 19358725 Apr 2009

“One hundred subjects in Russia will be treated with a combination of Combivir (zidovudine and lamivudine) and maraviroc as their first line HIV therapy.” NCT01275625

“For intolerance to Truvada, Combivir (zidovudine 300mg/lamivudine 150mg)will be available to be taken as 1 PO BID.” NCT00949234

Zidovudine (ZDV, Retrovir®) 10 mg/ml oral syrup administered twice daily at WHO weight band dose for 48 weeks” NCT01818258

“Trizivir® is a combination of three antiretroviral agents: Abacavir, Lamivudine and Zidovudine in a tablet.” NCT00865475

“patients who currently successfully use zidovudine (AZT) and lamivudine (3TC) as part of their regimen” NCT00389194

zidovudine, lamivudine, nevirapine or zidovudine, lamivudine if their mother is infected with HIV-2” NCT03642704

“Optimized NRTI recycling with lamivudine and one other NRTI (zidovudine or tenofovir or abacavir)” NCT03602690

“women received antenatal zidovudine and peripartum nevirapine, the standard of care at the time.” PMID 23324656 May 2013

“300 mg abacavir sulfate/150 mg lamivudine/300 mg zidovudine tablet taken orally twice daily” NCT00270296

“The second NRTI will be zidovudine unless the participant has a hemoglobin < 8 gm/dL” NCT00978068

“either zidovudine 300 mg BID if hemoglobin is ≥ 8 g/L or stavudine 30 mg BID” NCT01192035

“HAART: The first line was Zidovudine(AZT)+Lamivudine(3TC)+Efavirenz(EFV)” NCT01344148

“In the arms with NRTIs, 86% of patients received zidovudine/lamivudine.” PMID 19363330 Apr 2009

“both in combination with zidovudine/lamivudine 300/150 mg twice daily” PMID 23782005 Jul 2013

“Combivir® (lamivudine (LAM)/zidovudine (ZDV) coformulated)” NCT00708162

“lamivudine 150 mg plus zidovudine 300 mg BID dosed orally” NCT00246610

Zidovudine 300mg and lamivudine 150mg BID for 6 months” NCT00490620

“containing tenofovir, zidovudine and lamivudine” NCT00356616

“AZT/3TC/NVP (zidovudine/lamivudine/nevirapine)” NCT00428116

zidovudine 300 mg orally three times a day” NCT03922724

“zalcitabine (ddC), zidovudine (AZT)” NCT00039741

zidovudine (ZDV or AZT)” NCT03631732

zidovudine or stavudine” NCT01075152

Zidovudine (300 mg)” NCT01605084

zidovudine (ZDV)” NCT00006617

zidovudine (ZDV)” NCT02016924

Zidovudine (AZT)” NCT02231281

zidovudine (ZDV)” NCT06337032

ZidovudineNCT02231281

zidovudineNCT01637259

NCT00001354

NCT00000754

NCT00405925

NCT00122226

NCT00002378

NCT00217503

NCT00000664

NCT00017719

NCT00000728

NCT00002285

NCT00000662

NCT00000670

NCT00002096

NCT00000657

NCT00002199

NCT00000781

NCT00005764

NCT00001007

NCT00021463

NCT00001022

NCT00000718

NCT00000919

NCT00000659

NCT01386970

NCT04731103

NCT00000727

NCT00002312

NCT01641367

NCT00001075

NCT00013520

NCT00001024

NCT00002284

NCT00146380

NCT00000789

NCT00001025

NCT00002905

NCT00000716

NCT00000791

NCT00000671

NCT00011895

NCT00002286

NCT01618305

NCT01583439

NCT00002079

NCT00000656

NCT00000706

NCT00199121

NCT00000719

NCT00002376

NCT00002357

NCT00000652

NCT02431975

NCT02150993

NCT00003261

NCT00001644

NCT00002400

NCT01516970

NCT00000651

NCT00109590

NCT00650637

NCT00000918

NCT03088410

NCT00080522

NCT00167674

NCT00000800

NCT00000920

NCT00000649

NCT00075231

NCT00528957

NCT00672412

NCT00099632

NCT00000705

NCT00099359

NCT00002263

NCT00324649

NCT00002270

NCT00000703

NCT00158405

NCT00000770

NCT00000647

NCT00001029

NCT00000803

NCT02712801

NCT00001067

NCT01964755

NCT00001011

NCT00002379

NCT00002195

NCT00002401

NCT00000916

NCT02249416

NCT00966160

NCT00993031

NCT00000702

NCT00001010

NCT01061151

NCT00001066

NCT00120510

NCT00001008

NCT00000678

NCT00001083

NCT00002236

NCT00013897

NCT00000701

NCT00000700

NCT00000637

NCT00000810

NCT01352715

NCT00001084

NCT00000629

NCT00000765

NCT00002086

NCT00074581

NCT00041327

NCT00197613

NCT00004585

NCT00127959

NCT00000709

NCT00000628

NCT00002238

NCT00000731

NCT00000696

NCT00234923

NCT00001085

NCT00001032

NCT00409591

NCT00000625

NCT00002287

NCT00002288

NCT01694017

NCT00002190

NCT00001005

NCT00000720

NCT01125696

NCT00608569

NCT00028327

NCT00050895

NCT00000695

NCT00102206

NCT00000732

NCT00002162

NCT00001989

NCT00799864

NCT00002184

NCT02249130

NCT00000734

NCT00001003

NCT00001282

NCT00000685

NCT00915655

NCT00001002

NCT00002367

NCT00001035

NCT00335322

NCT00001001

NCT00002409

NCT00001993

NCT00002269

NCT00034086

NCT00000736

NCT00000999

NCT00002124

NCT00001036

NCT00001063

NCT00002436

NCT00000679

NCT00000995

NCT00031070

NCT00000994

NCT00424814

NCT00000923

NCT00002081

NCT00002391

NCT00001267

NCT00000993

NCT00014014

NCT00002410

NCT00000991

NCT00234091

NCT02363452

NCT02832778

NCT00000814

NCT00000694

NCT00014937

NCT00346567

NCT00000818

NCT00002411

NCT00084149

NCT00000823

NCT00001997

NCT00000990

NCT00002347

NCT00002208

NCT00000989

NCT00002524

NCT00719602

NCT00002320

NCT00002322

NCT00573001

NCT00002386

NCT00000693

NCT00000987

NCT00000760

NCT00000903

NCT01340950

NCT00002307

NCT00000723

NCT00000831

NCT00002183

NCT03988452

NCT00001087

NCT00000979

NCT00002001

NCT00144183

NCT00002435

NCT00000902

NCT00000680

NCT00002290

NCT00144157

NCT00005002

NCT00000834

NCT00038506

NCT01540240

NCT00043953

NCT00087945

NCT00002369

NCT00002168

NCT00273975

NCT00000838

NCT00001040

NCT00002063

NCT00143689

NCT00086359

NCT03394196

NCT00004736

NCT00002323

NCT00000986

NCT00000841

NCT01088516

NCT00078247

NCT00004999

NCT00470041

NCT00002443

NCT00002006

NCT00386230

NCT00004998

NCT00002007

NCT00002179

NCT00000983

NCT02499874

NCT00000855

NCT00854581

NCT00427297

NCT00001057

NCT00000755

NCT00272480

NCT00002013

NCT00002108

NCT00851630

NCT00000897

NCT00000982

NCT00002014

NCT00004981

NCT02737046

NCT00005000

NCT01419561

NCT00002324

NCT00000944

NCT00432016

NCT00002281

NCT00834457

NCT00002020

NCT00006264

NCT01772940

NCT00000864

NCT00000978

NCT00092222

NCT00000976

NCT00307151

NCT00342355

NCT00000687

NCT00000973

NCT00002048

NCT00002023

NCT00001045

NCT00002155

NCT00142337

NCT00002047

NCT00098293

NCT00006617

NCT00000865

NCT00936195

NCT00002046

NCT00001095

NCT00192660

NCT00005106

NCT00102960

NCT00002045

NCT00000971

NCT00084136

NCT00002044

NCT00192621

NCT00618176

NCT00002255

NCT00000891

NCT01441063

NCT00164736

NCT00000870

NCT00002109

NCT00000862

NCT00100594

NCT00001119

NCT00000711

NCT00002389

NCT00002326

NCT00192595

NCT00000753

NCT03178084

NCT00000738

NCT00000661

NCT00002334

NCT00001104

NCT00002033

NCT00000725

NCT00323544

NCT00000872

NCT01511237

NCT00000888

NCT02655471

NCT00002203

NCT00000682

NCT00002117

NCT02369406

NCT00162643

NCT00000967

NCT00000742

NCT00000751

NCT00000875

NCT00000681

NCT00000878

NCT00000952

NCT00000750

NCT00001106

NCT00000712

NCT00000965

NCT00100568

NCT00001048

NCT02181933

NCT00141284

NCT00002110

NCT00004852

NCT00001113

NCT00002035

NCT00002371

NCT00000887

NCT00000743

NCT00000882

NCT00000885

NCT00001112

NCT00000960

NCT00006396

NCT00001049

NCT00002034

NCT00000961

NCT00002276

NCT00001111

NCT00006441

Known as 3'-Azido-3'-Deoxythymidine “Phase I Trial of the Combination of 3'-Azido-3'-Deoxythymidine (Zidovudine) and Recombinant Interleukin-2” NCT00001005
Known as Azidothymidine “The purpose of this study is to see if giving azidothymidine (AZT) to HIV-positive patients with hemophilia is safe and if it is effective in lowering HIV levels and boosting...” NCT00000705
2

“A Clinical Study Examining the Pharmacokinetics and Bioavailability of Azidothymidine (AZT, Zidovudine) in Patients With Human Immunodeficiency Virus (HIV) Infection and Hepatic Disease” NCT00001001

“Study of Bleeding Tendency, Platelet Function, and Pharmacokinetics of Azidothymidine (AZT) and Motrin (Ibuprofen) in HIV-Infected Hemophiliacs” NCT00002276

Known as AZT “To evaluate the effect of anti-HIV immune serum globulin (HIVIG) versus immune globulin (IVIG) administered during pregnancy and to the newborn, in combination with zidovudine...” NCT00000751
171

“To determine if alternating zidovudine (AZT) and zalcitabine (dideoxycytidine; ddC) (first one and then the other) or intermittent therapy (1 week of drug then 1 week off) will...” NCT00000718

“The purpose of this study is to determine the short term safety, tolerance, and antiviral effect of zidovudine (AZT) and amdoxovir (AMDX, DAPD) in combination, and whether the...” NCT00432016

“To compare the effectiveness of zalcitabine ( dideoxycytidine; ddC ) therapy to zidovudine ( AZT ) in the treatment of AIDS or advanced AIDS related complex ( ARC ) in patients...” NCT00000678

“The investigators propose to evaluate the safety of combination therapy comprising the three nucleoside analog reverse-transcriptase inhibitors (NRTIs) zidovudine (AZT),...” NCT02363452

“To compare the efficacy of lamivudine (3TC) and zidovudine (AZT) in combination versus the better of didanosine (ddI) monotherapy or ddI/AZT combination, in symptomatic HIV-1...” NCT00001066

“To determine if the pharmacokinetics of low doses of zidovudine (AZT) (that is, how fast AZT reaches the blood, what concentration of AZT is attained in the blood, and how long...” NCT00000732

“Preliminary studies using human liver tissue have shown that valproic acid inhibits the metabolic inactivation of zidovudine (AZT), which may prolong the plasma half-life of...” NCT00000629

“To determine the effects of zidovudine (AZT) alone and in combination with didanosine (ddI) on viral load in the lymphoid tissue and blood of antiretroviral-naive, HIV-infected...” NCT00001057

“To evaluate the anti-HIV effect of single agent versus combination therapy with zidovudine (AZT) and interferon alfa-2a (IFN-A2a), as measured by p24 protein expression, viral...” NCT00000696

“Primary: To compare the efficacy of zidovudine ( AZT ) given alone versus AZT plus didanosine ( ddI ) versus AZT plus zalcitabine ( dideoxycytidine; ddC ) in delaying the...” NCT00001022

“The purpose of this study is to see if nevirapine (NVP) or zidovudine (AZT), given to mothers during labor and delivery and to their babies during the first week of life, can...” NCT00006396

“To determine the safety and efficacy of two doses of interferon alfa-2a ( IFN alfa-2a ) in combination with zidovudine ( AZT )/zalcitabine ( ddC ) versus AZT/ddC only in...” NCT00000754

“These study will explore how fast NVP is eliminated from women after delivery and to see if given zidovudine/lamivudine (AZT/3TC) for 1 or 2 weeks after NVP discontinuation can...” NCT00872872

“A Randomized, Double-Blind, Phase III Study of Indinavir Sulfate With Open-Label Zidovudine (AZT) and Lamivudine (3TC) in Subjects With HIV Infection With CD4 Cell Counts <=...” NCT00000841

“A Pilot Study to Evaluate the Immunologic Consequences of a Highly Active Antiretroviral Therapy Regimen (HAART) Consisting of Ritonavir (ABT-538), Zidovudine (AZT), and...” NCT00001075

“To evaluate the short-term effects of administering zidovudine ( AZT ) at the same time with increasing doses of aldesleukin ( interleukin-2; IL-2 ) in patients with persistent...” NCT00000728

“To show that zalcitabine (dideoxycytidine; ddC) is at least as effective as zidovudine (AZT) in the treatment of AIDS or advanced AIDS related complex (ARC), and also that ddC...” NCT00000679

“A Phase I Study to Evaluate the Pharmacokinetics, Safety and Antiviral Effects of Concurrent Administration of Zidovudine (AZT) and 2'3'-Dideoxyinosine (ddI) in Patients With...” NCT00002014

“An Open-Label, Non-Comparative Study of Saquinavir-SGC in Combination With Zidovudine (AZT) and Lamivudine (3TC) in the Treatment of HIV-1 Infected Patients With No Previous...” NCT00002367

“A Double-Blind Comparison of Zidovudine (AZT) Versus Stavudine (d4T; BMY 27857) for the Treatment of Patients With HIV Infection Who Have Absolute CD4 Lymphocyte Counts Between...” NCT00002307

“Forty patients currently taking zidovudine (AZT) or any other approved antiretroviral agent will be randomized to one of three treatment arms: high-dose nimodipine, low-dose...” NCT00000738

“To evaluate the safety and effectiveness of Retrovir (AZT) when used as prophylaxis for health care workers at risk for HIV infection from exposure to HIV-contaminated blood or...” NCT00002287

“The purpose of this study is to see if giving azidothymidine (AZT) to HIV-positive patients with hemophilia is safe and if it is effective in lowering HIV levels and boosting...” NCT00000705

“To study the use of acyclovir (ACV) and zidovudine (AZT) in the treatment of cytomegalovirus (CMV) retinitis in patients with AIDS who would otherwise be treated with...” NCT00000693

“zidovudine ( AZT ) versus didanosine ( ddI ), AZT plus ddI, and AZT plus zalcitabine ( ddC ) in preventing disease progression in HIV-infected patients with CD4 counts of...” NCT00000625

“To determine if methadone treatment will affect the blood levels of zidovudine (AZT) in patients with AIDS or AIDS-related complex (ARC) who are receiving oral AZT and...” NCT00001008

“A Clinical Study Examining the Pharmacokinetics and Bioavailability of Azidothymidine (AZT, Zidovudine) in Patients With Human Immunodeficiency Virus (HIV) Infection and Hepatic Disease” NCT00001001

“To compare the effect of stavudine (d4T) alone or with zidovudine (AZT) versus didanosine (ddI) alone or with AZT on CD4 counts, HIV RNA levels, and viral load in HIV-infected patients” NCT00001063

“To evaluate the safety and efficacy of low and high doses of lamivudine ( 3TC ) in combination with zidovudine ( AZT ) and zalcitabine ( dideoxycytidine; ddC ) in combination with AZT.” NCT00002436

“treatment with zidovudine (AZT) will delay or prevent the onset of AIDS or AIDS related complex (ARC) in individuals infected with HIV but who do not have symptoms of AIDS or ARC.” NCT00000736

“To evaluate the safety and efficacy of interferon beta (Betaseron) in AIDS and advanced AIDS related complex (ARC) patients receiving a reduced-dose zidovudine (AZT) regimen.” NCT00002238

“To prevent individuals who have had a massive accidental exposure to HIV from becoming infected with HIV and possibly developing AIDS, by treating them with zidovudine (AZT).” NCT00000993

“To determine the safety and effectiveness of combining zidovudine (AZT) and interferon alfa-2a (IFN-A2a) in a treatment for Kaposi's sarcoma (KS) in patients who have AIDS.” NCT00000687

“To evaluate and compare differences in tolerance and side effects associated with two different dosages of zidovudine (AZT) when used to treat children with HIV infection.” NCT00000983

“To determine whether there is a pharmacokinetic drug interaction between oral ganciclovir and oral zidovudine (AZT) and between oral ganciclovir and oral didanosine (ddI).” NCT00002096

“To define the pharmacokinetic parameters (blood levels) of total phosphorylated zidovudine (AZT) in peripheral blood mononuclear cells (PBMC) from HIV-infected patients.” NCT00000965

“A Pilot Study To Evaluate the Effect of Retrovir (Zidovudine: AZT) in the Treatment of Human Immunodeficiency Virus (HIV) Associated Dementia and Neuromuscular Diseases” NCT00002044

“To determine the safety and usefulness of zidovudine (AZT) for the treatment of patients with early symptomatic HIV infection or early AIDS related complex (ARC).” NCT00001011

“To determine the safety and tolerance of hyperimmune anti-HIV intravenous immunoglobulin (HIVIG) and of zidovudine (AZT) in infants with established HIV infection” NCT00000961

“treatment with zidovudine (AZT) compared to didanosine (ddI) and compared to the combination of AZT and ddI as determined by survival and disease progression” NCT00000637

“A Randomized, Open-Label Study of Alternative Treatment Combinations of Dideoxycytidine (HIVID; ddC) and Zidovudine (AZT) in Patients With HIV Infection” NCT00002117

“A Phase III Study to Evaluate the Safety, Tolerance, and Efficacy of Early Treatment With Zidovudine (AZT) in Asymptomatic Infants With HIV Infection” NCT00000750

“To evaluate the safety and tolerance of oral zidovudine (AZT) when given over a period of 24 weeks to children between 3 months and 12 years of age.” NCT00000716

“To determine the pharmacokinetics, safety, and efficacy of didanosine (ddI) alone or in combination with zidovudine (AZT) in HIV-infected infants.” NCT00001049

“Patients that are included are HIV infected and have started zidovudine (AZT) or didanosine (ddI) at least 4 weeks before entry into this study.” NCT00000971

“Study of Bleeding Tendency, Platelet Function, and Pharmacokinetics of Azidothymidine (AZT) and Motrin (Ibuprofen) in HIV-Infected Hemophiliacs” NCT00002276

“interactive effects of didanosine ( ddI ) or zalcitabine ( dideoxycytidine; ddC ) with zidovudine ( AZT ) on the pharmacokinetics of U-87201E” NCT00000753

“A Randomized, Comparative Trial of Zidovudine (AZT) Versus 2',3'-Didehydro-3'-Deoxythymidine (Stavudine; d4T) in Children With HIV Infection” NCT00000789

“Specifically, to evaluate zidovudine/zalcitabine ( AZT / ddC ) alone or in combination with either nevirapine or saquinavir ( Ro 31-8959 ).” NCT00002347

“Zidovudine (AZT) has previously demonstrated its effectiveness as a potent inhibitor of HIV replication in vitro and in adult patients” NCT00001106

“Open-Label Program of Dideoxycytidine ( ddC ) to Be Used in Combination With Zidovudine ( AZT ) for Treatment of Advanced HIV Disease” NCT00002081

“To determine the safety and tolerance of low-dose versus high-dose cysteamine administered concurrently with zidovudine (AZT).” NCT00002110

“To assess the safety and tolerance of the combination of zidovudine (AZT) and didanosine (ddI) in children with HIV infection.” NCT00000652

“The duration of clinical benefit from zidovudine (AZT) may be limited because of development of viral resistance to the drug.” NCT00000814

“To determine the safety and anti-HIV activity of two doses of SC-49483 in combination with zidovudine (AZT) versus AZT alone.” NCT00000791

“safety, tolerance, and pharmacokinetics of zidovudine (AZT) and zalcitabine (dideoxycytidine; ddC) when given in combination” NCT00001032

“An Open Trial of Zidovudine (AZT) Treatment of the AIDS Dementia Complex in Patients With AIDS or Low CD4+ Lymphocyte Counts” NCT00000709

“PRIMARY: To determine the maximum tolerated dose of interferon-alfa (IFN-A) alone and in combination with zidovudine (AZT)” NCT00000967

“The Safety and Effectiveness of Zidovudine (AZT) in the Treatment of HIV Infection in Patients With AIDS and Advanced ARC” NCT00000999

“nevirapine administered in combination with zidovudine (AZT) in mildly to moderately symptomatic HIV-infected children” NCT00001111

“To determine the safety and usefulness of zidovudine (AZT) for the treatment of children 3 months to 12 years of age.” NCT00000990

“Safety of Reduced Dose Zidovudine (AZT) Compared With Standard Dose AZT in Antiretroviral-naïve HIV-infected Patients” NCT01540240

“To test whether zidovudine (AZT) is useful as a treatment for the neurologic syndrome called AIDS dementia complex.” NCT00000702

“high-dose systemic methotrexate (MTX) and dexamethasone (DEX) combined with zidovudine (AZT) and brain irradiation” NCT00000723

“combination therapy for AIDS-associated Kaposi's sarcoma with zidovudine (AZT) and two kinds of interferon alpha” NCT00001113

“To evaluate the feasibility of Retrovir (AZT) in the treatment of psoriasis in HIV antibody positive patients.” NCT00002286

“To determine how zidovudine (AZT) for the treatment of HIV infection is metabolized and excreted or eliminated” NCT00000685

“To determine whether there is any additive toxicity with combined use of sCD4-PE40 and zidovudine (AZT).” NCT00000743

“patients who currently successfully use zidovudine (AZT) and lamivudine (3TC) as part of their regimen” NCT00389194

“chronic administration of Retrovir (AZT) to adult patients with early manifestations of HIV disease.” NCT00002045

“efficacy, safety, and pharmacokinetics of lamivudine (3TC) combined with zidovudine (AZT), stavudine” NCT00000838

“low-, moderate-, and high-dose schedules of zidovudine (AZT) plus didanosine (ddI) versus ddI alone” NCT00000656

“with or without daily oral zidovudine (AZT) or their current stable dose of antiretroviral therapy.” NCT00000755

“intravenous (IV) and oral zidovudine (AZT) can be safely given to children aged 1 day to 3 months” NCT00001007

“To determine the relationship of viral susceptibility to zidovudine (AZT) and baseline viral load” NCT00001025

“Combination Zidovudine (AZT) and 9-(2-Phosphonylmethoxyethyl)Adenine (PMEA; Adefovir) Treatment” NCT00002326

“combined administration of zidovudine (AZT) and increasing doses of recombinant interleukin-2” NCT00001005

“These treatments include zidovudine (AZT), which has been shown to control the HIV infection” NCT00001112

“To determine whether methadone maintenance alters the pharmacokinetics of zidovudine (AZT).” NCT00000800

“Patients continue to receive AZT at the dose prescribed prior to enrollment in the study.” NCT00000973

“Zidovudine (AZT) Versus AZT Plus Didanosine (ddI) Versus AZT Plus ddI Plus Nevirapine” NCT00001045

“concurrent oral Retrovir / Zovirax (AZT and ACV) therapy and oral AZT therapy alone” NCT00002290

“Primary: To determine the clinical effect of zidovudine (AZT) compared to placebo” NCT00002063

“Zidovudine (AZT) is administered orally 3 times daily at one of two dose levels.” NCT00000976

“compare the effectiveness and toxicity of didanosine (ddI) and zidovudine (AZT)” NCT00000671

“regimens of zidovudine ( AZT ) and 2',3'-dideoxycytidine ( zalcitabine; ddC )” NCT00000719

“combined oral zidovudine (AZT) and intermittent intravenous foscarnet therapy” NCT00001002

“Combivir (Zidovudine (AZT) plus lamivudine (3TC)) and nevirapine twice a day;” NCT00143689

“continuous oral zidovudine (AZT) treatment to HIV infected pregnant women” NCT00000960

“HAART: The first line was Zidovudine(AZT)+Lamivudine(3TC)+Efavirenz(EFV)” NCT01344148

“taking zidovudine (AZT) will change the natural course of HIV infection” NCT00000994

“high doses of zidovudine (AZT) (that is, how fast AZT reaches the blood” NCT00000734

“multiple oral doses of nevirapine in combination with zidovudine (AZT)” NCT00000649

“safety, tolerability, and activity of zidovudine (AZT) and zalcitabine” NCT00000978

“patients who have been taking zidovudine (AZT) alone for a long time” NCT00000831

“The study is designed to test the drug zidovudine (AZT) in children” NCT00000701

“zidovudine ( AZT ) and didanosine ( ddI ) alone and in combination” NCT00000823

“ganciclovir (GCV) and zidovudine (AZT) when given in combination.” NCT00000995

“To evaluate the interaction of probenecid with zidovudine (AZT).” NCT00000670

“combination of nevirapine and zidovudine (AZT) versus AZT alone” NCT00002323

“abacavir sulfate (ABC), lamivudine (3TC), and zidovudine (AZT)” NCT00084149

“Arm 1: Zidovudine (AZT), emtricitabine (FTC), efavirenz (EFV)” NCT00127959

“together with one of two different doses of zidovudine (AZT).” NCT00000987

“combination chemotherapy-radiation-zidovudine (AZT) treatment” NCT00000703

“zidovudine (AZT) and various doses of cancer-fighting drugs” NCT00000681

“zidovudine (AZT) plus AS-101 versus AZT alone (placebo arm)” NCT00002033

“Zidovudine (AZT) 600 mg orally q6 hours (every 6 hours)” NCT01441063

“when it is given at the same time as zidovudine (AZT)” NCT00000695

“in combination with zidovudine (AZT) versus AZT alone” NCT00002269

“Zidovudine (AZT), lamivudine (LAM), efavirenz (EFV)” NCT00192595

“of zidovudine (AZT) administered daily for 48 weeks” NCT00002020

“short-course zidovudine (AZT) and lamivudine (3TC)” PMID 19859531 Oct 2009

“continuous intravenous ( CIV ) zidovudine ( AZT )” NCT00002263

“Abacavir (ABC)+Lamivudine (3TC)+Zidovudine (AZT)” NCT04731103

“either zidovudine ( AZT ) or didanosine ( ddI )” NCT00000810

AZT/3TC/NVP (zidovudine/lamivudine/nevirapine)” NCT00428116

AZT/3TC/NVP (zidovudine/lamivudine/nevirapine)” NCT00427297

“Combivir (zidovudine [AZT] / lamivudine [3TC])” NCT00192621

“associated with zidovudine ( AZT ) treatment” NCT00002007

“antiretroviral effects of zidovudine (AZT)” NCT00000647

“concurrent treatment with zidovudine (AZT)” NCT00002034

“zidovudine ( AZT ) plus didanosine (ddI)” NCT00000781

“Retrovir Brand Zidovudine (AZT) Therapy” NCT00000662

“Zidovudine (AZT) & Interleukin-2 (IL2)” NCT00001282

“dose of zidovudine (AZT) that was used” NCT00000700

“between zidovudine (AZT) and oxazepam” NCT00000661

“orally administered zidovudine (AZT)” NCT00002035

“orally administered zidovudine (AZT)” NCT00000657

“zidovudine (AZT) is used by the body” NCT00000706

“patients receiving zidovudine (AZT)” NCT00000680

“zalcitabine (ddC), zidovudine (AZT)” NCT00039741

“Combivir (Zidovudine or AZT + 3TC)” NCT01088516

“zidovudine (AZT) versus didanosine” NCT00001997

“stable dose of zidovudine ( AZT )” NCT00002312

“zidovudine (AZT) plus zalcitabine” NCT00001029

“fixed doses of Zidovudine (AZT)” NCT00002322

“Interleukin-2/Zidovudine (AZT)” NCT00001354

“oral dose of zidovudine (AZT)” NCT00002023

“Zidovudine (AZT) Monotherapy” NCT00002320

“daily oral zidovudine (AZT)” NCT00001036

“zidovudine (AZT) treatment” NCT00000818

“Zidovudine (AZT) 300mg bid” NCT00618176

“low-dose Zidovudine (AZT)” NCT00001993

“zidovudine (AZT) therapy” NCT00000711

“zidovudine (ZDV or AZT)” NCT03631732

“zidovudine (AZT) alone” NCT00000712

“Drug: Zidovudine (AZT)” NCT00002524

“oral zidovudine (AZT)” NCT00000720

“plus zidovudine (AZT)” NCT00000991

“with zidovudine (AZT)” NCT00000725

“oral zidovudine (AZT)” NCT00000664

“zidovudine (AZT) IV” NCT00006264

“zidovudine ( AZT )” NCT00001067

“zidovudine ( AZT )” NCT00002357

“Zidovudine ( AZT )” NCT00000803

“zidovudine (AZT)” NCT00000731

“Zidovudine (AZT)” NCT00002270

“Zidovudine (AZT)” NCT00002281

“Zidovudine (AZT)” NCT00002155

“Zidovudine (AZT)” NCT00002443

“Zidovudine (AZT)” NCT00002334

“zidovudine (AZT)” NCT00005000

“zidovudine (AZT)” NCT00002013

“Zidovudine (AZT)” NCT02231281

“zidovudine (AZT)” NCT00000770

“zidovudine (AZT)” NCT00001040

“zidovudine (AZT)” NCT00000628

“zidovudine (AZT)” NCT00000742

“Zidovudine (AZT)” NCT00002255

“zidovudine (AZT)” NCT00002124

“zidovudine; AZTNCT00002435

Known as Retrovir “100 patients will be randomized to receive Zerit (Stavudine) + Epivir (Lamivudine) + Crixivan (Indinavir) and 100 patients will be randomized to receive Retrovir (Zidovudine) +...” NCT00002369
8

“A Multi-Center, Double-Blind Trial to Evaluate the Safety and Efficacy of Concurrent Retrovir (Zidovudine) and Zovirax (Acyclovir) Therapy in Patients With Early Symptomatic...” NCT00002290

“To evaluate the safety and effectiveness of Retrovir (AZT) when used as prophylaxis for health care workers at risk for HIV infection from exposure to HIV-contaminated blood or...” NCT00002287

“A Pilot Study To Evaluate the Effect of Retrovir (Zidovudine: AZT) in the Treatment of Human Immunodeficiency Virus (HIV) Associated Dementia and Neuromuscular Diseases” NCT00002044

“To evaluate the feasibility of Retrovir (AZT) in the treatment of psoriasis in HIV antibody positive patients.” NCT00002286

“chronic administration of Retrovir (AZT) to adult patients with early manifestations of HIV disease.” NCT00002045

“300 mg zidovudine (Retrovir tablets, GlaxoSmithKline)” NCT00966160

Retrovir Brand Zidovudine (AZT) Therapy” NCT00000662

Retrovir (Zidovudine)” NCT00002168

Known as Retrovir(R) “Zidovudine, or Retrovir(R), is used at a high dose.” NCT00092222
Known as ZCV “Zidovudine (ZCV)” NCT00144183
Known as ZDV “Additional ARVs provided for use in this study included fixed dose combination lamivudine/zidovudine (3TC/ZDV), lamivudine (3TC), zidovudine (ZDV), tenofovir (TDF), fixed dose...” NCT00955968
67

“Participants will receive 2 investigator-selected NRTIs, which may include abacavir (ABC), lamivudine (3TC)/zidovudine (ZDV), didanosine (DDI), emtricitabine (FTC), ABC/3TC,...” NCT01363011

“The purpose of this study is to see if it is safe to give saquinavir-SGC (SQV) combined with low-dose ritonavir (RTV) plus zidovudine (ZDV) and lamivudine (3TC) to HIV-positive...” NCT00000920

“A Double-Blind, Randomized, Multicenter Trial to Evaluate the Safety and Efficacy of the Combination of 1592U89/Zidovudine (ZDV)/Lamivudine (3TC) Versus the Combination of...” NCT00002391

“The efficacy and tolerance of switching from zidovudine (ZDV) and lamivudine (3TC) in clinically stable HIV-infected children with incomplete viral suppression to stavudine...” PMID 11840078 Feb 2002

“Arm I options are enteric-coated didanosine (ddI-EC) plus lamivudine (3TC), ddI-EC plus zidovudine (ZDV), ZDV plus 3TC (or Combivir), stavudine (d4T) plus 3TC, or ddI-EC plus...” NCT00014937

“Double reverse transcriptase inhibitor (RTI) therapy consisting of any two therapy combinations of: didanosine (ddI), lamivudine (3TC), stavudine (d4T) or zidovudine (ZDV),...” NCT00002376

“The purpose of this study is to compare the safety and effectiveness of taking lamivudine (3TC) plus zidovudine (ZDV) plus a protease inhibitor (PI) with taking the 3TC/ZDV...” NCT00002203

“The purpose of this study is to see if it is safe and effective to give ritonavir (RTV) plus lamivudine (3TC) plus zidovudine (ZDV) to HIV-infected pregnant women during...” NCT00000888

“The extent and manner by which HIV nucleoside reverse transcriptase inhibitors contribute to insulin resistance is unclear. We evaluated the effect of zidovudine/lamivudine...” PMID 19898246 Feb 2010

“Treatment-naive adults were randomized to nevirapine (NVP) or ritonavir-boosted lopinavir (LPV/r) regimens each in combination with tenofovir (TDF)/emtricitabine (FTC) or...” PMID 25028911 May 2014

“A Phase I Trial of the Safety, Tolerance, and Pharmacokinetics of Oral Nelfinavir (Viracept) Co-Administered With Zidovudine (ZDV) and Lamivudine (3TC) in HIV Infected Pregnant...” NCT00000887

“A Randomized, Double Blind, Comparative Study of Dideoxycytidine (ddC) Alone or ddC/AZT Combination Versus Zidovudine (ZDV) Alone in Patients With HIV Infection Who Have...” NCT00000651

“Subjects (2 to <16 years) on a stavudine (d4T) or zidovudine (ZDV) containing regimen with HIV-1 RNA <400 copies/mL were randomized to either switch d4T or ZDV to TDF or...” PMID 25760565 Apr 2015

“A Phase II Study to Evaluate the Safety, Tolerance and Efficacy of Hyperimmune Anti-HIV Intravenous Immunoglobulin (HIVIG) and of Zidovudine (ZDV) in Infants With Documented...” NCT00000961

“The nucleoside analogue combinations provided on this study are as follows: zidovudine (ZDV) plus didanosine (ddI), ZDV plus lamivudine (3TC), stavudine (d4T) plus 3TC, or d4T plus ddI.” NCT00000923

“The purpose of this study is to look at the effects of different methods of birth control (oral and injectable) on how the body absorbs, makes available, and removes zidovudine (ZDV).” NCT00000897

“Patients receive specific combinations of 3 or 4 of the following 6 drugs: didanosine (ddI), stavudine (d4T) efavirenz (EFV), nelfinavir (NFV), lamivudine (3TC), or zidovudine (ZDV).” NCT00000919

“A sensitive LC/MS/MS assay for determining zidovudine (ZDV) and lamivudine (3TC) in human plasma was validated to support antiretroviral pharmacology research programs.” PMID 21465499 Apr 2011

“Patients receiving combination antiretroviral therapy with indinavir (IDV), zidovudine (ZDV)(or d4T) and lamivudine (3TC) show viral suppression for two years or more.” NCT00000916

“A Study to Test the Safety, Tolerance, and Metabolism of Abacavir (1592U89, ABC) With Standard Zidovudine (ZDV) Therapy in Newborn Infants Born to HIV-1 Infected Women” NCT00000864

“Study A: To determine whether treatment with zidovudine (ZDV) will delay or change the disease process in hemophilic patients who have HIV infection with no symptoms.” NCT00001104

“The purpose of this study is to examine the safety and tolerability of ZDV when given to premature infants born to HIV-positive women to prevent HIV infection.” NCT00000855

“300 mg of zidovudine (ZDV), 150 mg of lamivudine, and 200 mg nevirapine (NVP) was given twice daily from 34 weeks gestation until six months after delivery.” NCT00167674

“receive abacavir sulfate/lamivudine/zidovudine (ABC/3TC/ZDV) twice-daily or atazanavir (ATV) once-daily plus lamivudine/zidovudine (3TC/ZDV) twice-daily.” PMID 19358725 Apr 2009

“Most HIV-positive pregnant women usually take the anti-HIV drug zidovudine (ZDV) to treat HIV and reduce the chances of giving HIV to their babies.” NCT00000878

“A Feasibility Study of Lamivudine/Zidovudine (3TC/ZDV) Plus Efavirenz (EFV) as Initial Therapy of HIV-1 Infected Patients in a Rural Area of China” NCT00100594

“The two combinations are abacavir/lamivudine/zidovudine (ABC/3TC/ZDV) and zidovudine/lamivudine (ZDV/3TC) plus lopinavir/ritonavir (LPV/RTV).” NCT00086359

“Fixed dose combination abacavir/lamivudine/zidovudine (ABC/3TC/ZDV) among HIV-1 and tuberculosis (TB)-coinfected patients was evaluated” PMID 20001518 Dec 2009

“oral ZDV and to determine whether the oral administration of Zidovudine (ZDV) during labor and delivery will provide a similar profile” NCT00000862

“All patients will receive open label induction therapy with zidovudine (ZDV), lamivudine (3TC) and indinavir (IDV) for 6 months.” NCT00001084

“The combination of ZDV/3TC (Combivir®) and Lopinavir/ritonavir (LPV/r) (Kaletra® or Aluvia®) is chosen as a reference regimen” NCT00936195

“Arm A - 141W94, plus Zidovudine (ZDV) and Lamivudine (3TC) or Arm B - 141W94, plus ZDV placebo and 3TC placebo.” NCT00001085

“Zidovudine (ZDV, Retrovir®) 10 mg/ml oral syrup administered twice daily at WHO weight band dose for 48 weeks” NCT01818258

“Stavudine (d4T) + Lamivudine (3TC) + Zidovudine placebo or Zidovudine (ZDV) + Lamivudine + Stavudine placebo” NCT00002371

“Zidovudine (ZDV) and lamivudine (3TC) metabolism to triphosphates (TP) is necessary for antiviral activity.” PMID 17664328 Jul 2007

“The drugs to be used in combination with DLV are zidovudine (ZDV), indinavir (IDV), and lamivudine (3TC).” NCT00002401

“A Phase I Trial To Evaluate Zidovudine (ZDV) in HIV-1 Infected Pregnant Women and Their Offspring” NCT00001106

“tenofovir (TDF) + emtricitabine (FTC) + zidovudine (ZDV) + abacavir (ABC)” NCT00335322

“observational data suggest benefit from zidovudine (ZDV) therapy” NCT00099359

“abacavir (ABC)/lamivudine (3TC)/zidovudine (ZDV)/efavirenz (EFV)” NCT00013520

ZDV (Zidovudine 300 mg) 1 tb BID (mornings and evenings orally)” NCT02150993

“those treated with zidovudine (ZDV) and those treated with ddI.” PMID 8229656 Nov 1993

“delavirdine (DLV) plus indinavir (IDV) plus zidovudine (ZDV)” NCT00002236

“Combivir® (lamivudine (LAM)/zidovudine (ZDV) coformulated)” NCT00708162

“zidovudine (ZDV), stavudine (D4T) and lamivudine (3TC)” NCT00001095

“indinavir plus lamivudine (3TC) plus zidovudine (ZDV)” NCT00000944

“DMP 266 plus zidovudine (ZDV) plus lamivudine (3TC)” NCT00002410

“lamivudine (3TC)/zidovudine (ZDV)/1592U89 arm” NCT00002199

“zidovudine (ZDV)-exposed uninfected children” PMID 25838291 Apr 2015

“oral zidovudine (ZDV) at the onset of labor” NCT00109590

“Lamivudine (3TC) and Zidovudine (ZDV)” NCT00002389

“zidovudine (ZDV or AZT)” NCT03631732

“Drug: Zidovudine (ZDV)” NCT02181933

“zidovudine (ZDV)” NCT02016924

“Zidovudine (ZDV)” NCT02249130

“Zidovudine (ZDV)” NCT01061151

“zidovudine (ZDV)” NCT00002386

“zidovudine (ZDV)” NCT00004736

“Zidovudine (ZDV)” NCT00158405

“Zidovudine (ZDV)” NCT00000865

“zidovudine (ZDV)” NCT00002208

“zidovudine (ZDV)” NCT06337032

“Zidovudine (ZDV)” NCT00142337

“Zidovudine (ZDV)” NCT00000882

“Zidovudine (ZDV)” NCT00002124

“zidovudine (ZDV)” NCT00006617

“Zidovudine (ZDV)” NCT00000891

Known as ZDV: zidovudine, azidothymidine, Retrovir ZDV: zidovudine, azidothymidine, RetrovirNCT02028676
Action Inhibit “previous studies have shown AZT to be an effective inhibitor of HIV reverse transcriptase” NCT00000695
Modality Small molecule “nucleoside analog” NCT00000781
Route Oral “AZT orally every 8 hours on days 1 through 4” NCT00000629